Neutropenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX

被引：0
|
作者：
Shitara, K. [1 ]
Matsuo, K. [1 ]
Takahari, D. [1 ]
Yokota, T. [1 ]
Ura, T. [1 ]
Muro, K. [1 ]
机构：
[1] Aichi Canc Ctr, Nagoya, Aichi 464, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4115
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX
    Shitara, Kohei
    Matsuo, Keitaro
    Takahari, Daisuke
    Yokota, Tomoya
    Inaba, Yoshitaka
    Yamaura, Hidekazu
    Sato, Yozo
    Najima, Mina
    Ura, Takashi
    Muro, Kei
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (10) : 1757 - 1763
  • [2] Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab
    Bousahba, A.
    Behourah, Z.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer
    Aparicio, Jorge
    Fernandez-Martos, Carlos
    Vicent, Jose M.
    Maestu, Inmaculada
    Llorca, Cristina
    Busquier, Isabel
    Campos, Jan M.
    Perez-Enguix, Daniel
    Balcells, Miquel
    CLINICAL COLORECTAL CANCER, 2005, 5 (04) : 263 - 267
  • [4] Oxaliplatin,Fluorouracil and Leucovorin (FOLFOX) as First-line Chemotherapy for Metastatic or Recurrent Colorectal Cancer Patients
    Bing Han Ruihua Xu Yanxia Shi Huiyan Luo Xiaojuan Xiang Yuhong Li Li Zhang Tongyu Lin Youjian HeDepartment of Medical Oncology
    Chinese Journal of Clinical Oncology, 2007, (06) : 397 - 400
  • [5] KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy
    Sharma, Neelesh
    Saifo, Maher
    Tamaskar, Ila R.
    Bhuvaneswari, Ramkumar
    Mashtare, Terry
    Fakih, Marwan
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2010, 1 (02) : 90 - 96
  • [6] Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer
    Vaidyanathan, Gayatri
    Groman, Adrienne
    Wilding, Gregory
    Fakih, Marwan G.
    ONCOLOGY, 2010, 79 (1-2) : 67 - 71
  • [7] Identification of an immunological prognostic factor for metastatic colorectal cancer patients treated with first-line oxaliplatin-based chemotherapy
    Tada, K.
    Shoji, H.
    Kitano, S.
    Nishimura, T.
    Shimada, Y.
    Nagashima, K.
    Ito, A.
    Honma, Y.
    Iwasa, S.
    Okita, N.
    Takashima, A.
    Kato, K.
    Yamada, Y.
    Katayama, N.
    Boku, N.
    Heike, Y.
    Hamaguchi, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S80 - S80
  • [8] Muscle volume loss after the induction of first-line chemotherapy as a novel prognostic factor in metastatic colorectal cancer patients
    Yoshikawa, Yusuke
    Okabayashi, Koji
    Hasegawa, Hirotoshi
    Tsuruta, Masashi
    Seishima, Ryo
    Takahashi, Hidena
    Yamada, Toru
    Matsui, Shimpei
    Kondo, Takayuki
    Shimada, Takehiro
    Matsuda, Mutsuhito
    Yahagi, Masashi
    Asada, Yusuke
    Sugiura, Kiyoaki
    Suzuki, Yoshiyuki
    Tajima, Yuki
    Nakadai, Junpei
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [9] Chemotherapy efficacy in metastatic colorectal cancer (mCRC) patients treated with adjuvant or first-line FOLFOX-based chemotherapy.
    Samalin, Emmanuelle
    Tien Tuan Nguyen
    Thezenas, Simon
    Portales, Fabienne
    Mazard, Thibault
    Gourgou, Sophie
    Assenat, Eric
    Ychou, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Place of first-line palliative chemotherapy in patients with metastatic colorectal cancer
    Hebbar, M
    REVUE DE MEDECINE INTERNE, 1997, 18 : S364 - S367
12345